IGC Pharma
26 hedge funds and large institutions have $937K invested in IGC Pharma in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
574% more call options, than puts
Call options by funds: $128K | Put options by funds: $19K
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.26% less ownership
Funds ownership: 5.81% → 5.55% (-0.26%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
28% less capital invested
Capital invested by funds: $1.31M → $937K (-$373K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$26.6K |
| 2 |
Millennium Management
New York
|
+$25.5K |
| 3 |
Jane Street
New York
|
+$9.64K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$7.22K |
| 5 |
BlackRock
New York
|
+$4.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$52K |
| 2 |
Renaissance Technologies
New York
|
-$40.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.36K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$6.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$6.36K | -15,583 | Closed |
|
IGC Hedge Fund Activity: Q4 2022 in Review
26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2022, worth a combined $937K — down 28% from $1.31M a quarter earlier.
Fund positioning in IGC was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $26.6K. The largest seller was Vident Investment Advisory, exiting entirely with an estimated $52K sold.
- 26 institutional investors held IGC Pharma (IGC) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $937K of IGC Pharma stock for Q4 2022, down 28% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q4 2022 and 4 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q4 2022 was Virtu Financial, an estimated $26.6K added.
- The largest IGC Pharma seller in Q4 2022 was Vident Investment Advisory, an estimated $52K sold.
Based on aggregated 13F filings for Q4 2022.